-

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Rivian Automotive, Inc. (RIVN) Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Rivian Automotive, Inc. (“Rivian” or the “Company”) (NASDAQ: RIVN) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s November 2021 initial public offering (“IPO” or the “Offering”). Rivian investors have until May 6, 2022 to file a lead plaintiff motion.

Investors suffering losses on their Rivian investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

On November 10, 2021, Rivian conducted its initial public offering (“IPO”), selling 153 million shares of common stock for $78.00 per share.

On March 1, 2022, Rivian announced that it was raising the prices of its R1T pickup by 17% and its R1S SUV by 20%, and that the new prices would apply to nearly all preorders. At the time of the announcement, Rivian had only produced and sold roughly 1,000 vehicles while the number of preorders for the R1T and R1S had grown to approximately 71,000 as of December 15, 2021. The Company’s chief growth officer explained that the price increase was due to “inflationary pressure, increasing component costs, and unprecedented supply chain shortages and delays for parts.”

Then, on March 2, 2022, ARS Technica published an article stating that “[w]hile inflation is likely part of the story, the price hike may have been planned for a while,” citing a lawsuit by Rivian’s former VP of sales and marketing alleging that “concerns over profitability were raised in spring 2021.”

On this news, Rivian’s stock fell $8.41, or 13.5%, to close at $53.56 per share on March 2, 2022, thereby injuring investors.

Then, on March 3, 2022, Rivian’s CEO apologized to customers and stated that the Company would honor original prices for preorders placed prior to the price increase announcement. But an article by The Wall Street Journal reported that some customers who had cancelled their orders did not reinstate them “[e]ven after learning that [their] original price would be honored.”

On this news, Rivian’s stock price fell $2.65 and currently trades significantly below the IPO price.

The complaint filed alleges that the Registration Statement made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the Registration Statement failed to disclose: (i) that Rivian had underpriced the R1T and R1S to such a degree that Rivian would be forced to raise prices shortly after the IPO; (ii) the potential for significant reputational damage and cancellation of fully refundable preorders for the R1T and R1S that would result from Company’s need to address its underpriced EVs by raising prices shortly after the IPO; and (iii) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you purchased Rivian common stock, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Law Offices of Howard G. Smith

NASDAQ:RIVN

Release Versions

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

More News From Law Offices of Howard G. Smith

Law Offices of Howard G. Smith Encourages Lufax Holding Ltd. (LU) Shareholders To Inquire About Securities Fraud Class Action

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Lufax Holding Ltd. (“Lufax” or the “Company”) (NYSE: LU) securities between April 7, 2023 and January 26, 2025, inclusive (the “Class Period”). Lufax investors have until May 20, 2026 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN LUFAX HOLDING LTD. (LU), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE...

Law Offices of Howard G. Smith Encourages Gemini Space Station, Inc. (GEMI) Shareholders To Inquire About Securities Fraud Class Action

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of Gemini Space Station, Inc. (“Gemini” or the “Company”) (NASDAQ: GEMI) investors who purchased Class A common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about September 12, 2025 (the “IPO” or “Offering”) and/or securities between September 12, 2025 and February 17, 2026, inclu...

Law Offices of Howard G. Smith Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) securities between May 20, 2024 and January 9, 2026, inclusive (the “Class Period”). Atara investors have until May 22, 2026 to file a lead plaintiff motion.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ATARA BIOTHERAPEUTICS, INC. (ATRA), CONTACT THE LAW OFFICES OF HOWARD G. S...
Back to Newsroom